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Abstract 
 Chemotherapy in itself is suspected to cause the development or 
selection of drug-resistant tumor cells, which have more aggressive phenotypes. 
The authors investigated the differential changes of gene expression in the 
1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea 
(ACNU)-resistant subline of the C6 rat glioma (C6AR2), which was established 
from C6 rat glioma cells by exposure to ACNU in vitro. The resistance to ACNU 
of C6AR2 was confirmed by MTS assay. The increased expression of  
O6-methylguanine-DNA methyltransferase in C6AR2 cells was shown using 
RT-PCR. C6AR2 cells displayed a higher proliferative activity relative to C6 cells. 
Analysis with cDNA array showed that 19 genes were transcriptionally 
up-regulated and 16 genes down-regulated in C6AR2 cells compared to C6 cells. 
They belonged to various functional classes of genes beside the drug-resistant 
system. Among them, the down-regulation of several genes in C6AR2 cells, 
including c-kit, pleiotrophin, platelet-derived growth factor receptor-D, peripheral 
myelin protein-22 and NG2 chondroitin sulfate proteoglycan, which are 
expressed originally in developmental glial linages, were verified using 
semi-quantitative RT-PCR. In addition, the gene expression of astroglial 
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intermediate filament proteins, including GFAP, vimentin and nestin, were 
decreased in C6AR2 cells relative to C6 cells in semi-quantitative RT-PCR and 
immunocytochemistry. These findings may represent an undifferentiated state of 
ACNU-resistant glioma cells and a more aggressive phenotype in recurrent 
tumors following chemotherapy.  
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Abbreviations 
 
ACNU (nimustine), 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)- 
3-nitrosourea; BCNU (carmustine), 1,3-bis(2-chloroethyl)-1-nitrosourea; GFAP, 
glial fibrillary acidic protein; MIF, macrophage migration inhibitory factor; MTS, 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium, inner salt]; NG2, NG2 chondroitin sulfate proteoglycan;  
O6-MGMT, O(6)-methylguanine-DNA methyltransferase; PDGFRD, platelet- 
derived growth factor receptor-D; PMP-22, peripheral myelin protein 22; PTN, 
pleiotrophin. 
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 Malignant gliomas are the most common type of primary brain tumors. 
Despite aggressive multimodal treatment, including gross total resection, 
radiation therapy, and chemotherapy, malignant gliomas are almost uniformly 
fatal; the median survival time is about one year [1]. Most of these patients die of 
local tumor recurrence or regrowth, which in most cases is difficult to treat. 
Although gliomas have a tendency to increase in malignancy during their natural 
course, recurrent glioma may increase in malignancy compared with the original 
tumor, possibly in relation to its therapy. Chemotherapy is suspected of having 
an effect on the generation of phenotypical heterogeneity as well as the 
development of drug resistance in tumors. Recently, Saito et al. [2] reported that  
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-resistant 9L rat glioma cells 
displayed a more invasive phenotype. Many studies have shown the differential 
expression changes of drug resistance-related genes in glioma cells aquiring 
drug resistance [3]. However, there have been few reports about gene 
expression changes beside drug resistance-related genes [4]. In Japan, 
1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea 
(nimustine hydrocloride, ACNU) is the most common chemotherapeutic agent 
used in glioma therapy [5,6]. In this study, we developed an ACNU-resistant C6 
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rat glioma cell line and investigated its differential changes of gene expression.  
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Materials and Methods 
 
Drugs 
 ACNU was supplied by Sankyo Drug Co. (Tokyo, Japan). It was 
solubilized in distilled water and stored at -80 °C until use. 
 
Cells 
 The C6 rat glioma cell line was obtained from the American Type Culture 
Collection (Rockville, MD, USA). A C6 subline resistant to ACNU (C6AR2) was 
established by continuously exposing the cell line to graded concentrations of 
ACNU. These cells were maintained in Dulbecco’s modified Eagle’s minimum 
essential (DME) medium (Sigma, St Louis, MO, USA) supplemented with 10% 
FBS at 37 °C and 5% CO2. 
 
Chemosensitivity testing by MTS assay 
 The sensitivity of C6 and C6AR2 cells was tested using the MTS cell 
proliferation assay kit (Promega, Madison, WI, USA). C6 and C6AR2 cells in the 
logarithmic growth phase were plated in 96-well plates in a volume of 100 μl at 
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1.5 x 103 cells/well. ACNU was added 16 h later. After incubation for 72 h at 37 
˚C, the medium was removed from each well and the cells were incubated in a 
CO2 incubator for 2 h with 100 μl fresh medium and 20 μl MTS solution, and the 
absorbance at 490 nm was measured with spectrophotometry. The 50% lethal 
dose (IC50) for each cell line was determined from the dose-response curves. 
 
Proliferation assay 
 The proliferative activity of C6 and C6AR2 cells was measured using an 
MTS assay.  C6 and C6AR2 cells in the logarithmic growth phase were plated 
in 96-well plates in a volume of 100 μl at 0.5 x 103 cells/well. After incubation for 
24, 48 and 72 h at 37 ˚C, MTS activity was determined as described above. 
 
RNA isolation and cDNA microarray 
 Total RNA was extracted from cultured glioma cells according to the 
manufacturer’s instructions for TRIZOL Reagent (Invitrogen, Carlsbad, CA, 
USA). Poly-A+ mRNA was isolated and converted to cDNA in the presence of 
[α-32P] dATP using an Atlas Pure Total RNA Labeling System according to the 
manufacturer’s protocol (Clontech, Palo Alto, CA, USA). The array membranes 
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(Rat 1.2k Array, Clontech) were prehybridized for 30 min at 68°C in ExpressHyb, 
followed by hybridization with the labeled cDNAs overnight at 68°C, washing 
three times with pre-warmed 2 x saline sodium citrate buffer (SSC) – 1 % sodium 
dodecylsulfate (SDS) at 68°C for 30 min, once with 0.1 x SSC - 0.5 % SDS for 
30 min, and finally with 2 x SSC at room temperature for 5 min. The membranes 
were immediately wrapped with plastic film, and exposed to a PhosphorImager 
screen. The screens were scanned using a Molecular Dynamics Storm 
Phosphorimager and the image data were analyzed with AtlasImage 2.0 
software (Clontech). After orientation and alignment of the two array membranes, 
the array background was subtracted using a local background setting of 200% 
for all array images (the intensity of spots three-fold greater than the background 
intensity is significant), and the intensity of the detected genes on each 
membrane was adjusted by the normalization coefficient, which was calculated 
based on the intensity of all genes.  The data were obtained from the average 
normalized values of two experiments using AtlasImage.  A composite array 
from duplicate experiments was prepared using AtlasImage software and the 
ratio of intensity between the different groups was determined. In our study, the 
ratios were calculated as C6AR2/C6. When the direction of change in signal 
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levels obtained with two experiments was consistent and the C6AR2/C6 ratio 
was ≥ 2.0, it was set as significant up-regulation; if the ratio was ≤ 0.5, it was set 
as significant down-regulation. If the signal from one of the arrays was under the 
background intensity, an intensity difference ≥ 20 (C6AR2 minus C6) was 
defined as up-regulation and a difference ≤ -20 as down-regulation. 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 Total RNA was extracted from cultured glioma cells according to the 
manufacturer’s instructions for TRIZOL Reagent. Two μg of total RNA were 
converted to first strand cDNA using a Reverse Transcription System (Promega). 
The resulting cDNA was subjected to PCR analysis using a Taq PCR Master Mix 
Kit (Qiagen, Valencia, CA, USA). Each cycle consisted of 30 s at 94°C for 
denaturation, 30 s at 60°C for annealing, and 60 s at 72°C for extension. A 
negative control reaction without reverse transcription was also performed. The 
PCR products were stained with ethidium bromide after agarose gel 
electrophoresis and photographed using Polaroid film type 667. The intensity of 
ethidium bromide fluorescence was measured using NIH Image 1.62 program. 
The cycle number was chosen such that amplification of the products was in the 
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linear range with respect to the amount of input cDNA. The levels of target 
mRNAs were normalized to the level of cyclophilin mRNA in the same sample 
[7,8]. The actual sequences of specific primers are as follows: 
O6-MGMT  (sense) 5’-ATTAGCAGCCCTGGCAGGCAACCC-3’ 
  (antisense)5’-GAAGACTCGAAGGATGGCTTGAGCC-3’ 
Fas  (sense) 5’-TGCACCAACCTGCCATCCGTGCAC3 
  (antisense) 5’-CTCAAGGATGTCTTCAAGTCCACACG-3’ 
MIF  (sense) 5’- CCGGCACAGTACATCGCAGTGCAC-3’ 
  (antisense) 5’- CCCACGTTGGCTGCGTTCATGTCG-3’ 
c-kit  (sense) 5’- TGGCGTTTCCTACGTCGTACCAACC-3 
  (antisense) 5’-CTCTCCGGTGCCATCCACTTCACG-3’ 
PTN  (sense) 5’-CTGTGGAGAATGGCAATGGAGTGTG-3’  
  (antisense) 5’-CTGACAGTCGGCATTGTGCAGAGC-3’ 
PDGFRD (sense) 5’- GAGCCAGGAGACGAGGTATCAAAGC-3 
  (antisense) 5’-TGCAGATCATCCACTCGATGTTCGG-3’ 
PMP-22  (sense) 5’-ACTGTACCACATCCGCCTTGGGAG-3’ 
  (antisense) 5’- GTCGTTGTTGACATGCCACTCACTG -3’ 
NG2  (sense) 5’- GTGTTTGACTGTGCACTGGGCTCT-3’ 
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  (antisense) 5’- GGCTTTGGTCCCATCTCAACAAAC-3’ 
GFAP   (sense) 5’-GCCGCTCCTATGCCTCCTCCGA-3’, 
  (antisense) 5’-TCCAGCGACTCAACCTTCCTCT-3’ 
vimentin  (sense) 5’-GGTGGATCAGCTCACCAATGACAAG-3 
  (antisense) 5’-GCAAGGATTCCACTTTACGTTCAAGG-3’ 
nestin  (sense) 5’-AGAGGTGACCCTTGGGTTAGAGGC-3’ 
  (antisense) 5’-ATGGACTCAGACTCTTCATGGCCC-3’ 
cyclophilin (sense) 5’-GGGGAGAAAGGATTTGGCTA-3’ 
  (antisense) 5’-AGAGATTACAGGGTATTGCGAG-3’ 
 
Immunocytochemistry 
 Tumor cells cultured on Lab-Tek chamber slides (Nalge Nunc 
Internatinal, Rochester, NY, USA) were fixed for 15 min at room temperature in 
2% paraformaldehyde. The Envision system (DAKO, Carpinteria, CA, USA) was 
used for immunocytochemistry. Briefly, the culture slides were washed free of 
fixative with phosphate-buffered saline (PBS, pH 7.4), exposed to 0.3 % H2O2 in 
PBS for 5 minutes to inactivate endogeneous peroxidase, then incubated in 
blocking solution (DAKO) for 5 minutes. The slides were then reacted with 
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primary antibodies for 2 h at room temperature. Dilutions of primary antibodies 
were 1:1000 for anti-GFAP polyclonal antibody (DAKO), 1:200 for anti-vimentin 
monoclonal antibody (DAKO), and 1:100 for anti-nestin monoclonal antibody 
(BD Biosciences, San Jose, CA, USA). Secondary antibodies labelled with 
horseradish peroxidase (DAKO) were applied to the slides for 1 h. The color was 
developed with 0.02% 3-3’ diaminobenzidine tetrahydrochloride and 0.03% H2O2 
in PBS. The slides were counterstained with Mayer’s hematoxylin. Between 
steps, the slides were washed three times in PBS. Slides incubated with normal 
mouse or rabbit serum in place of the primary antibody served as negative 
controls. 
 
Statistical analysis 
 Data are expressed as the mean ± standard error (SEM). Statistical 
differences were compared between those of C6 and C6AR2 cells using 
Student’s t-test. A value of p < 0.05 was considered statstically significant. 
 14 
Results 
 
Sensitivity for ACNU of C6 and C6AR2 cells 
Compared to C6 cells, C6AR2 cells showed an increased resistance to 
ACNU treatment. IC50 for ACNU of C6 was 5.0 ± 0.3 μg/ml and that of C6AR2 
was 155.9 ± 12.6 μg/ml, respectively (Fig.1). Since O6-MGMT induction is an 
important mechanism for resistance to ACNU, we investigated the expression of 
O6-MGMT in C6 and C6AR2 cells using RT-PCR. In C6AR2 cells the expression 
of O6-MGMT was up-regulated relative to C6 cells (Fig.2)  
 
Proliferative activity of C6 and C6AR2 cells 
 As shown in Fig.3, C6AR2 displayed a higher proliferative activity than 
C6 cells. 
 
cDNA array analysis 
 Among 1,176 genes represented on the cDNA array, 397 genes were 
detected in C6 and 240 genes in CA6R2 cells (Fig.4), with differences in 
expression levels for 35 genes in C6AR2 cells relative to those in C6 cells 
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according to our criteria.  Out of 35 genes, 19 genes were up-regulated and 16 
genes down-regulated in C6AR2 compared to those of C6. Genes were 
categorized based on their reported or suggested functions and placed into one 
of 11 broad functional groups (Table 1 and 2) [9]. 
 The direction of change in the mRNA levels of several genes, including 
Fas, MIF, c-kit, PTN, PMP-22 and PDGFRD, obtained with the RT-PCR results 
was consistent with that from the cDNA array results (Figs. 4, 5 and 6, Tables 1 
and 2).  
 
Down-regulation of several genes in developmental astro-  and oligo-glial 
linages 
 Since the cDNA array showed that several genes (c-kit, PTN, PMP-22 
and PDGFRD), which are expressed in developmental glial cells, were 
down-regulated in C6AR2 cells relative to C6 cells, we further studied about 
additional markers of glial linages, including NG2, GFAP, vimentin and nestin, 
using semi-quantitative RT-PCR. The expresssion of these genes was 
decreased in C6AR2 cells compared to C6 cells (Fig.6). In addtion, 
immunocytochemistry demonstrated that C6AR2 cells were immunonegative for 
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GFAP and vimentin, while their immunoreactivity for nestin remained relative 
(Fig. 7).  
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Discussion 
 
 The chemotherapic agent ACNU is one of the most commonly used 
against malignant gliomas in Japan [5,6]. However, most patients suffer from 
local recurrence or regrowth of their tumors following ACNU treatment. 
Furthermore, generally these recurrent tumors have a more aggressive 
phenotype, which is usually much more difficult to control. Although diverse 
processes are considered to be involeved in the tumor recurrece, chemotherapy 
in itself may result in the selection or induction of tumor cells with more 
malignant characteristics. In fact, Saito et al. [2] reported 
(1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU))-resistant 9L rat glioma cells, which 
were implanted into the rat brain, displayed a more invasive phenotype 
compared to wild-type 9L cells. 
 In the present study, to investigate the differential changes of gene 
expression in C6 glioma cells with the acquisition of resistance to ACNU, we 
compared gene expression between wild- and ACNU resistant-type of C6 cells, 
using cDNA array. In addition to the up-regulation of O6-MGMT in C6AR2 cells 
shown by RT-PCR, cDNA array demonstrated that the expression of glutathione 
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S-transferase S, which is also one of enzymes for resistance to ACNU [3], was 
increased in C6AR2 cells compared to C6 cells. Beside this drug-resistance 
related gene, the cDNA array showed us changes of other functional genes in 
C6AR2 cells. Among them, we noticed that c-kit, PMP-22 and PDGFRD, which 
are expressed in oligodendroglial progenitor cells [10-14], were down-regulated 
in C6AR2 cells relative to C6 cells on the cDNA array. The expression of PTN, 
which is expressed mainly in developmental astroglial cells [15,16], was also 
decreased in C6AR2 cells compared to C6 cells. We verified these changes 
using semi-quantitative RT-PCR. Additionally, we showed that the expression of 
NG2, which is also expressed in oliodendroglial linages [12,13] and astroglial 
intermediate filamant proteins, including GFAP, vimentin and nestin, was 
down-regulated in C6AR2 cells compared to C6 cells. These findings suggest 
that C6AR2 cells express less developmental oligo- and astro-glial markers. In 
general, more malignant gliomas express less glial markers. Malignant astrocytic 
tumors are often GFAP negative, and many high-grade gliomas seem to lose 
GFAP expression [17-20]. GFAP-negative cells proliferate more rapidly than 
GFAP-positive cells in the same tumor [21,22]. In the present study, 
GFAP-negative C6AR2 cells also proliferated more rapidly than GFAP-positive 
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C6 cells. Recently, using laser capture microdissection and cDNA array, 
Hoelzinger et al. [23] reported that GFAP and vimentin are down-regulated 
transcriptionally in invasive glioma cells as compared to the tumor core 
population. These findings suggest that undifferentiated glioma cells induced by 
chemotherapeutic agents may also display a more aggressive phenotype. 
 In summary, we found decreased expressions of glial marker genes in 
ACNU-resistant C6 glioma cells. This finding may represent the undifferentiated 
state of these cells, although it is not known whether C6 glioma cells are 
dedifferentiated when they aquire ACNU resistance or whether undifferenciated 
cells are selected under ACNU exposure, and more aggressive phenotypes in 
recurrent tumors in clinical cases. In addtion, in this study, the cDNA array 
showed differential expression changes of various functional genes other than 
drug-resistance and glial marker genes. Although the cellular events from these 
changes remains unknown, further studies in this field might provide us an 
attractive choke point for alternative therapies against malignant gliomas.  
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Figure Legends 
 
Fig.1 Graph demonstrating the survival of C6 and C6R2 cells after treatment 
of ACNU. The surviving fractions were determined by MTS assay, as described 
in the Materials and Methods. Values are the mean ± SEM for n=4; the 
experiment was repeated three times. Where no SEM bar is visible, the SEM 
was too small to be graphed. C6AR2 cells showed an increased resistance to 
ACNU exposure relative to C6 cells. 
 
Fig.2 RT-PCR analysis for the O6-MGMT gene in C6 and C6AR2 cells. Total 
RNA was extracted and reverse-transcribed, followed by PCR with specific 
primers. Cyclophilin served as the unchanging control mRNA. Relative 
quantitation values of these mRNA levels were normalized with respect to 
cyclophilin gene expression, and the results of three independent experiments 
are summarized as a bar graph. Data are expressed as the mean ± SEM. The 
expression of O6-MGMT gene was increased in C6AR2 cells compared to C6 
cells. 
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Fig.3 Growth curve of C6 and C6AR2 cells. The cell number for each 
experiment was determined by MTS assay and is shown as a ratio to the 
number of tumor cells that had been grown in the media. Values are the mean ± 
SEM for n=4; the experiment was repeated three times. Asterisks denote values 
significant between C6 and C6AR2 cells at same incubation times (p<0.05). 
Where no SEM bar is visible, the SEM was too small to be graphed. C6AR2 cells 
proliferated more rapidly than C6 cells. 
 
Fig.4 Phosphoimages of the expression pattern of genes in C6 (A, top) and 
C6AR2 (B, bottom) cells. Differential hybridization of two identical Atlas Rat 1.2 
cDNA expression Arrays was carried out. This is a representative result from one 
of two experiments. Arrows (A) and close-up images (B) indicate several genes 
differentially expressed in glioma cells: 1,  Fas; 2, MIF; 3, c-kit; 4, PTN; 5, 
PMP-22; 6, PDGFRD. 
 
Fig.5 Verification of cDNA array results with semi-quantitative RT-PCR. Two 
up-regulated genes, Fas and MIF, in C6AR2 cells and two down-regulated 
genes, c-kit and PTN, in those were selected from cDNA array results. 
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Cyclophilin was used as the unchanging mRNA. Relative quantitation values of 
these mRNA levels were normalized with respect to cyclophilin gene expression, 
and the results of three independent experiments are summarized as a bar 
graph. Data are expressed as the mean ± SEM. Asterisks denote values 
significant between those of C6 and C6AR2 cells (p<0.05). The direction of 
change in mRNA levels obtained with the RT-PCR results was consistent with 
that from the cDNA array results. 
 
Fig.6 RT-PCR analysis for genes expressed in developmental oligo- and 
astro-glial cells, including PMP-22, PDGFRD, NG2, GFAP, vimentin and nestin. 
Total RNA was extracted and reverse-transcribed, followed by PCR with specific 
primers. Cyclophilin served as the unchanging control mRNA. Relative 
quantitation values of these mRNA levels were normalized with respect to 
cyclophilin gene expression, and the results of three independent experiments 
are summarized as a bar graph. Data are expressed as the mean ± SEM. 
Asterisks denote values significant between those of C6 and C6AR2 cells 
(p<0.05). Where no SEM bar is visible, the SEM was too small to be graphed. 
The gene expression of glial markers was down-regulated in C6AR2 cells 
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relative to C6 cells. 
 
Fig.7 Photographs of immunocytochemistry for astroglial intermediate filament 
proteins (A and D, GFAP; B and E, vimentin; C and F, nestin) in C6 (A, B and C) 
and C6AR2 (D, E and F) cells. Bars represent the length of 50 Pm. 
Immunoreactivity for GFAP and vimentin was lost in C6AR2 cells, while that for 
nestin remained relatively. 
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Table 1.     Genes up-regulated in C6AR2 
 
Gene Families and Names   GenBank  Ratio  
 
Apoptosis, DNA-binding and cell cycle-regulating proteins 
fas antigen (APO-1)    D26112    2.0 
G1/S-specific cyclin D3 (CCND3)  D16309   2.0 
LIM domain protein CLP36   U23769   2.5 
 
Hormone, neurotransmitters and receptors 
inositol triphosphate receptor subtype 3 L06096     2.3 
insulin receptor     M29014   2.0 
 
Immune system proteins 
macrophage migration inhibitory factor (MIF) U62326   2.0 
 
Metabolism 
glutathione S-transferase P subunit  X02904    2.0 
glutathione S-transferase Yb subunit  J02592     3.0 
glutathione transferase subunit 8  X62660    2.0 
glycerol kinase     D16102   2.5 
squalene epoxidase    D37920   2.0 
 
Proteases and protease inhibitors 
amonipeptidase B    U61696   2.0 
 
Signal transduction 
beta-arrestin 1     M91589   2.5 
casein kinase II alpha subunit   L15618     2.0 
NVP-3 (neural visinin-like protein 3)  D13126   2.1 
protein kinase C-zeta    M18332   2.0 
 
Translation and protein turn-over 
proteosome component C13   D10729   2.0 
 
Transporters and carrier proteins 
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Insulin-like growth factor binding protein-1  
    (IGFBP1) M89791   2.2 
Na+/K+ ATPase beta 3 subunit   D84450   4.9    
 
Genes up-regulated in C6AR2 cells relative to C6 cells. Data were obtained 
from quantification of cDNA arrays using the Atlas Image software after 
normalization. Gene expression was calculated by determing the average of 
the ratio of C6AR2/C6 from the results of duplicate experiments. 
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Table 2.     Genes down-regulated in C6AR2 
 
Gene Families and Names   GenBank  Ratio  
 
Adhesion molecules, cytoskeletons and ECMs 
peripheral myelin protein 22 (PMP-22)  M69139   0.2 
 
Apoptosis, DNA-binding and cell cycle-regulating proteins 
G1/S-specific cyclin D1 (CCND1)  D14014   0.3 
high mobility protein 2 (HMG2)   D84418   0.4 
 
Growth factors and growth factor receptors 
c-kit          0.5 
PDGF receptor alpha (PDGFRD)  M63837   0.5 
pleiotrophin (PTN)    M55601     Down -74* 
 
Metabolism 
cytochrome c oxidase Vb & VIa precursor D10592+X14208  0.3 
mitochondrial ATPase synthase beta subunit M19044   0.5 
 
Proteases and protease inhibitors 
tissue carboxypeptidase inhibitor (TCI)  U40260   0.2 
 
Signal transduction 
14-3-3 protein eta (PKC inhibitor protein-1) D17445   0.5 
PDGF-associated protein   U41744   0.4 
 
Transcription 
DNA-binding protein inhibitor ID-1  D10862   0.4 
DNA-binding protein inhibitor ID-3  D10864   0.5 
 
Translation and protein turn-over 
proteasome subunit RC10-II   D21800   0.5 
 
Transporters and carrier proteins 
epidermal fatty acid binding protein (E-FABP) U13253   Down -21* 
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Na+/K+ ATPase alpha1 subunit   M28647   0.5    
 
Genes down-regulated in C6AR2 cells relative to C6 cells. Data were obtained 
from quantification of cDNA arrays using the Atlas Image software after 
normalization. Gene expression was calculated by determing the average of 
the ratio of C6AR2/C6 from the results of duplicate experiments. 
* Down : Difference between signal intensity of C6AR2 and C6 (a ratio could not 
be calculated because the signal of C6AR2 was below background). 
 33 
Fig.1 
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Fig.3 
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Fig.4 
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Fig.5 
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Fig.6 
 
 
 39 
Fig.7 
 
 
 
